Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Tian Zhang, Lei Xu, Kentaro Imai, Christian Heinrich Poehlein, Thomas Powles
Institutions: Harvard University, Dana-Farber Cancer Institute, Poznan University of Medical Sciences, Samsung Medical Center, Sungkyunkwan University, Beatson West of Scotland Cancer Centre, University of Glasgow, Fiona Stanley Hospital, Edinburgh Cancer Research, University of Edinburgh, University Hospital Ostrava, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Besançon, Hôpital Saint-André, Fundación Arturo López Pérez, University of Pennsylvania Health System, Abramson Cancer Center, Provincial Polyclinical Hospital in Toruń, The University of Texas Southwestern Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4324136207